Aptamers are a new class of molecules with a great potential to rival monoclonal antibodies in therapeutic, diagnostic, analytical as well as basic research applications. Described just over two decades ago, there has been an ever growing interest in these molecules as evidenced by the considerable increase in the number of related publications. Furthermore, the field of aptamer technology received a great boost in 2004 after the first FDA approved drug, Macugen, to treat age related macular degeneration, and later the development of the first aptamer based diagnostic platform for the analysis of mycotoxins in grain. In subsequent years there has been an outstanding growth in the Aptamer based companies and the range of developed products. Aptamers 2014 was our first international meetings at Oxford that brought together the aptamer community from both academia and industry and solution providers. The meeting was chaired by Professor Said Ismail (University of Jordan, Amman, Jordan) and also witnessed the launch of The International Society on Aptamers, which will provide a dedicated platform and a focal point to aptamer researchers and industrial partners for interaction and collaboration. Based on the excellent success of Aptamers 2014, we are pleased to announce our second annual symposium on Aptamers, Aptamers 2015, which will be held at St Hilda’s College on 31 March – 01 April 2015. The symposium will be co-hosted with our first symposium on antisense and catalytic nucleic acids, Oligomer 2015.